Ισραήλ - Αγγλικά - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 2000 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.

Ισραήλ - Αγγλικά - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 250 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.

Ισραήλ - Αγγλικά - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 500 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

grifols malaysia sdn. bhd. - factor viii/antihaemophilic factor/ahf -

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

csl behring gmbh - factor viii (antihaemophilic factor) von willebrand factor - pdr+solv for soln for inj - 500iu vial international unit

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

csl behring gmbh - factor viii (antihaemophilic factor) von willebrand factor - solution for infusion - 1000iu via international unit

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor ix, quantity: 1000 iu - injection, powder for - excipient ingredients: phosphate; plasma proteins; antithrombin iii; heparin sodium; sodium; citrate; chloride - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor ix, quantity: 500 iu - injection, powder for - excipient ingredients: citrate; heparin sodium; antithrombin iii; sodium; chloride; plasma proteins; phosphate - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Ισραήλ - Αγγλικά - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii - powder and solvent for solution for injection - factor viii 1000 iu/vial - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).this preparation does not contain von willebrand factor in pharmacologically effective quantities and is therefore not indicated in von willebrand’s disease.

Ισραήλ - Αγγλικά - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii - powder and solvent for solution for injection - factor viii 500 iu/vial - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)this preparation does not contain von willebrand factor in pharmacologically effective quantities and is therefore not indicated in von willebrand's disease.